Dementia Medication De-Listed in France: Untruth, Half-Truth or Paternalistic News Blackout? (BBC News / Prescrire / ADI / Inside Health / JAMA Network Open)

Summary

Early evening headlines yesterday, on BBC Radio 4 news, announced the “shocking” news that drugs for Alzheimer’s Disease / dementia had been de-listed in France. This story has not been followed-up, and appears to have been dropped quietly; although neither, apparently, has it been retracted or corrected in any transparent manner.

So far as can be discerned, the source of this news is not particularly new. The veracity of this particular news item cannot be verified conclusively, although – if true – it seems odd that no-one has brought this to the attention of UK / world audiences sooner.

“The drugs available in mid-2018 for Alzheimer’s Disease have only minimal and transient efficacy. They have disproportionate, serious and sometimes fatal adverse effects. …In May 2018, France’s Minister for Health took this negative harm-benefit balance into account. She decided that, from 1 August 2018, these drugs – donepezil, galantamine, rivastigmine and memantine – would be delisted, i.e. no longer reimbursed by the national health insurance system”.

Full Text Link

Reference

Drugs for Alzheimer’s disease: finally delisted in France! [Online]: Prescrire in English [the Prescriber], June 15th 2018. [Médicaments de la maladie d’Alzheimer: enfin non remboursables en France!] Rev. Prescrire. 2018: 38(416).

Corroborative Evidence – Five Months Old

Circumstantial evidence, dating from late May 2018, confirms that the story does indeed have some basis, and may be true (if inexplicably belated):

Full Text Link

Reference

Alzheimer’s Disease International (ADI) pledges to register anti-dementia drugs on WHO list of essential medicines. [Online]: Alzheimer’s Disease International, May 30th 2018.

Postscript – Proof Positive: October 2018 Update

Mystery explained; BBC News must have been reflecting / promoting the BBC Radio Four network’s own programme content from earlier the same day:

Full Text Link

Reference

France Delists Alzheimer’s Drugs, Quality of Life After Hip Fracture, Prostate Cancer. London: BBC Radio 4’s Inside Health, October 17th 2018.

The latest NICE guideline on the subject was released in June 2018, so will not be updated in the light of these developments for some time to come.

Monotherapy Versus Combination Therapy?

Uncertain clinical significance…

Full Text Link

Reference

Lawler, E. [and] Avila, A. (2018). Alzheimer Disease: Monotherapy vs. Combination Therapy. American Family Physician. April 1st 2017; 95(7): 452.

Possibly of interest:

Full Text Link

Reference

Kennedy, RE. Cutter, GR. [and] Fowler, ME. [et al] (2018). Association of concomitant use of cholinesterase inhibitors or Memantine with cognitive decline in Alzheimer clinical trials: a meta-analysis. JAMA Network Open, 1(7), pp.e184080-e184080.

Galantamine-Memantine Drug Combination Superior to Donepezil-Memantine Combination?

The search for alternative drug combinations continues. For example:

Full Text Link

Reference

Koola, MM. Nikiforuk, A. [and] Pillai, A. [et al] (2018). Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. Journal of Geriatric Care and Research (JGCR). 2018, Vol.5(2): pp.57-67.

Earlier:

Full Text Link

Reference

Hager, K. Baseman, AS. [and] Nye, JS. [et al] (2018). Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimer’s Research and Therapy. November 15th 2016; 8(1): 47.

Advertisements

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Alzheimer’s Disease International (ADI), Universal Interest and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.